Chongqing pharmaceutical company approved 2.4 billion glucocorticoid injection Pfizer half of the remaining?

Pharmaceutical Network June 28 - June 23, Chongqing Lemmy Pharmaceuticals issued a notice that recently received the State Drug Administration approved the issuance of injection sodium methyl olere nylon sodium "drug registration approval", Minet data show that in China's public medical institutions terminal methyl oleosteroid top1 products, including injections in 2019 sales of nearly 2.4 billion yuan.Table 1:Essentials of PharmaceuticalSource: Company Announcement
Company Announcement, it is known that injected sodium meldonium nylon is a synthetic glucocorticoid developed by PHARMACIA AND UPJOHN, now part of Pfizer Pharmaceuticals, and first listed in the United States in 1959, the product is called SOLU-MEDROLThe product is mainly used in anti-inflammatory treatment (e.grheumaticdiseases
, glider diseases, skin diseases, etc.), immunosuppressive therapy (organ transplantation), blood diseases (acquired hemolytic anemia, adult spontaneous thropoonism, adult secondary hairplatelet reduction, etc.), tumors (adult leukemia and lymphoma,childrenacute leukemia treatment treatment), shock treatment, endocrine disordersSodium methyl-sprinklenylon amber ate is easily soluble in water, is used for intravenous or intramuscular injection, is rapidly hydrolysated in plasma, and plays a pharmacological role in the form of free methyl-spraying nylonCompared with penisonol, in addition to the pharmacological effects of glucocorticoids, there is a stronger anti-inflammatory effect and weaker water and sodium retention.Figure 1: Sales of sodium methyl-sulene sodium amber acid in injections (units: 10,000 yuan)Source: Minnet China's public medical institutions terminal competition pattern
Minet net data show that china's urban publichospitals
county-level public hospitals, urban community centers and township health hospitals (china public medical institutions) terminal injection of sodium methylperunate in 2018 sales have exceeded 2 billion yuan, in 2019 to 2.37 billion yuan growth in the growth rate of 2.37 billion yuan.The market share of leadingcompaniesPfizer declined from 62.64 percent in 2015 to 50.07 percent in 2019, still accounting for half of the shares of domestic pharmaceutical companies, with the market share of China Pharmaceuticals And Jinsheng Pharmaceuticals and Tianjin Jinyao Pharmaceuticals accounting for 26.31 percent and 11.25 percent, respectively.Source: Company Announcement, Minet Database.